Primary Myelofibrosis (PMF) Completed Phase 3 Trials for Ruxolitinib (DB08877)

Also known as: Primary Myelofibrosis / Primary Myelofibrosis (MF) / Myelofibrosis (PMF) / Myelofibrosis, Primary / PMF / Osteomyelofibrosis / Primary myelofibrosis (disorder) / Myelofibrosis (disorder) / Primary myelofibrosis (morphologic abnormality)

IndicationStatusPhase
DBCOND0044387 (Primary Myelofibrosis (PMF))Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01969838Momelotinib Versus Ruxolitinib in Subjects With MyelofibrosisTreatment
NCT02087059A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) MyelofibrosisTreatment